Suppr超能文献

急诊科中的β-内酰胺类抗生素试验剂量

Beta-lactam antibiotic test doses in the emergency department.

作者信息

Maguire Michelle, Hayes Bryan D, Fuh Lanting, Elshaboury Ramy, Gandhi Ronak G, Bor Sarah, Shenoy Erica S, Wolfson Anna R, Mancini Christian M, Blumenthal Kimberly G

机构信息

Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

出版信息

World Allergy Organ J. 2020 Jan 7;13(1):100093. doi: 10.1016/j.waojou.2019.100093. eCollection 2020 Jan.

Abstract

BACKGROUND

Facilitating beta-lactam antibiotic use in patients reporting beta-lactam allergies in acute care settings is important to individual patient outcomes and public health; however, few initiatives have targeted the Emergency Department (ED) setting.

METHODS

We implemented pathways for patients reporting prior penicillin and/or cephalosporin hypersensitivity as part of a hospital guideline in the ED of a large academic medical center in the United States. We described beta-lactam test doses, pathway compliance, hypersensitivity reactions (HSRs), and allergy record updating associated with ED-administered beta-lactam test doses from October 2016 to June 2018.

RESULTS

310 beta-lactam antibiotic test doses were administered to patients with penicillin and/or cephalosporin allergy histories in the study period (average volume 15/month [standard deviation 4]). Test doses were to cephalosporins (85%), penicillins (12%), and carbapenems (4%). 219 (71%) of test doses were compliant with the pathways. Ten patients (3.2%; 95% CI 1.6%-5.9%) had HSRs; five HSR patients (50%) had beta-lactams administered that were not pathway compliant. The allergy record was updated in 146 (47%) of patients, with improvement over the study period (p < 0.001).

CONCLUSIONS

Inpatient approaches to prescribing beta-lactams in patients reporting beta-lactam allergies can be operationalized in the ED. Additional efforts are required to ensure guideline compliance and appropriate allergy documentation.

摘要

背景

在急症护理环境中,促进对报告有β-内酰胺类抗生素过敏的患者使用β-内酰胺类抗生素,对患者个体预后和公共卫生都很重要;然而,很少有举措针对急诊科(ED)环境。

方法

作为美国一家大型学术医疗中心急诊科医院指南的一部分,我们为报告有青霉素和/或头孢菌素过敏史的患者实施了相应路径。我们描述了β-内酰胺类试验剂量、路径依从性、过敏反应(HSR)以及与2016年10月至2018年6月急诊科给予的β-内酰胺类试验剂量相关的过敏记录更新情况。

结果

在研究期间,对有青霉素和/或头孢菌素过敏史的患者给予了310次β-内酰胺类抗生素试验剂量(平均每月15次[标准差4])。试验剂量用于头孢菌素(85%)、青霉素(12%)和碳青霉烯类(4%)。219次(71%)试验剂量符合路径要求。10名患者(3.2%;95%CI 1.6%-5.9%)发生了过敏反应;5名发生过敏反应的患者(50%)接受的β-内酰胺类药物给药不符合路径要求。146名(47%)患者的过敏记录得到更新,且在研究期间有所改善(p<0.001)。

结论

对于报告有β-内酰胺类过敏的患者,住院患者开具β-内酰胺类药物的方法可在急诊科实施。需要进一步努力以确保指南依从性和适当的过敏记录。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5222/6950835/872ea46043f7/gr1a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验